Panelists discuss that, based on EMERALD trial data, elacestrant provides consistent clinical benefit in metastatic breast ...

Allelic frequencies and heterozygosities were determined for each marker loci and compared between Korean, ... including allelic frequency and heterozygosity, ... Table 1 summarizes the ...

Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer ... (1,185/3,262 alts).

Background: Mutations in PTPN11, encoding tyrosine phosphatase SHP2, are present in 4-6% of AML. Largest report includes 27 patients (pts). Methods: Analysis included AML patients (pts) treated at MD ...